Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 9

1.

Modelling of early viral kinetics and pegylated interferon-alpha2b pharmacokinetics in patients with HBeag-positive chronic hepatitis B.

ter Borg MJ, Hansen BE, Herrmann E, Zeuzem S, Cakaloglu Y, Karayalcin S, Flisiak R, van' t Veen A, de Man RA, Schalm SW, Janssen HL, Haagmans BL; HBV 99-01 Study Group.

Antivir Ther. 2007;12(8):1285-94.

PMID:
18240868
[PubMed - indexed for MEDLINE]
2.

Peginterferon alpha-2b is safe and effective in HBeAg-positive chronic hepatitis B patients with advanced fibrosis.

Buster EH, Hansen BE, Buti M, Delwaide J, Niederau C, Michielsen PP, Flisiak R, Zondervan PE, Schalm SW, Janssen HL; HBV 99-01 Study Group.

Hepatology. 2007 Aug;46(2):388-94.

PMID:
17604363
[PubMed - indexed for MEDLINE]
3.

Successful treatment with peginterferon alfa-2b of HBeAg-positive HBV non-responders to standard interferon or lamivudine.

Flink HJ, Hansen BE, Heathcote EJ, Feinman SV, Simsek H, Karayalcin S, Mach T, Leemans WF, de Man RA, Verhey E, Schalm SW, Janssen HL; HBV 99-01 Study Group.

Am J Gastroenterol. 2006 Nov;101(11):2523-9. Epub 2006 Oct 4.

PMID:
17029610
[PubMed - indexed for MEDLINE]
4.

Patterns of viral decline during PEG-interferon alpha-2b therapy in HBeAg-positive chronic hepatitis B: relation to treatment response.

ter Borg MJ, van Zonneveld M, Zeuzem S, Senturk H, Akarca US, Simon C, Hansen BE, Haagmans BL, de Man RA, Schalm SW, Janssen HL; HBV 99-01 Study Group.

Hepatology. 2006 Sep;44(3):721-7.

PMID:
16941701
[PubMed - indexed for MEDLINE]
5.

Peg-interferon improves liver histology in patients with HBeAg-positive chronic hepatitis B: no additional benefit of combination with lamivudine.

van Zonneveld M, Zondervan PE, Cakaloglu Y, Simon C, Akarca US, So TM, Flink HJ, de Man RA, Schalm SW, Janssen HL; HBV 99-01 Study Group.

Liver Int. 2006 May;26(4):399-405.

PMID:
16629642
[PubMed - indexed for MEDLINE]
6.

Treatment with Peg-interferon alpha-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype.

Flink HJ, van Zonneveld M, Hansen BE, de Man RA, Schalm SW, Janssen HL; HBV 99-01 Study Group.

Am J Gastroenterol. 2006 Feb;101(2):297-303.

PMID:
16454834
[PubMed - indexed for MEDLINE]
7.

Flares in chronic hepatitis B patients induced by the host or the virus? Relation to treatment response during Peg-interferon {alpha}-2b therapy.

Flink HJ, Sprengers D, Hansen BE, van Zonneveld M, de Man RA, Schalm SW, Janssen HL; HBV 99-01 Study Group.

Gut. 2005 Nov;54(11):1604-9. Epub 2005 May 29.

PMID:
15923670
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

The safety of pegylated interferon alpha-2b in the treatment of chronic hepatitis B: predictive factors for dose reduction and treatment discontinuation.

van Zonneveld M, Flink HJ, Verhey E, Senturk H, Zeuzem S, Akarca US, Cakaloglu Y, Simon C, So TM, Gerken G, de Man RA, Hansen BE, Schalm SW, Janssen HL; HBV 99-01 Study Group.

Aliment Pharmacol Ther. 2005 May 1;21(9):1163-71.

PMID:
15854180
[PubMed - indexed for MEDLINE]
Free Article
9.

Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial.

Janssen HL, van Zonneveld M, Senturk H, Zeuzem S, Akarca US, Cakaloglu Y, Simon C, So TM, Gerken G, de Man RA, Niesters HG, Zondervan P, Hansen B, Schalm SW; HBV 99-01 Study Group; Rotterdam Foundation for Liver Research.

Lancet. 2005 Jan 8-14;365(9454):123-9.

PMID:
15639293
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk